MedTrace Logo

Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma

NCT00492076 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2008-10-16

No results posted yet for this study

Summary

The purpose of this study is to determine whether a short course of subcutaneous immunotherapy is efficacious in mite induced asthma. The efficacy is based on reduction in control medication.

Conditions

  • Allergic Asthma

Interventions

BIOLOGICAL

Pangramin Plus D. pteronyssinus 100%

1. Active. Pangramin Plus D. pteronyssinus 100% 2. Placebo. Pangramin Plus placebo

Sponsors & Collaborators

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • Ana I Tabar, MD PhD · Hospital Virgen del Camino

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00492076 on ClinicalTrials.gov